

Jeremy Powell  
Project Manager  
Centre for Health Technology Evaluation  
National Institute for Health and Clinical Excellence  
MidCity Place  
71 High Holborn  
London  
WC1V 6NA

20<sup>th</sup> February 2009

Dear Jeremy,

**Response to the Appraisal Consultation Document 2:  
Lenalidomide for the treatment of multiple myeloma in people who have received at least one  
prior therapy from Macmillan Cancer Support**

1. We are delighted that the recently issued second ACD on the use of lenalidomide for the treatment of multiple myeloma is positive for people who have received two or more prior therapies. This is a small patient group and we feel that this second Appraisal Consultation Document reflects their needs.
2. We do however remain concerned that as stated in point 4.2 of the ACD “the optimal sequence of agents to use is as yet unclear and depends on several factors, including a person’s treatment history, co-morbidities and disease characteristics.” The Committee found lenalidomide to be cost-ineffective in patients at first relapse. However, we would urge the Committee to reconsider this in relation to the small group of patients for whom bortezomib is not suitable at first relapse.
3. We are pleased that the manufacturer has offered a price-capping scheme for lenalidomide to ensure that this important treatment is more affordable to the NHS.

If you require further information please contact [REDACTED], [REDACTED], [REDACTED].

Yours sincerely,

[REDACTED]  
Macmillan Cancer Support